Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own2.60% Shs Outstand61.43M Perf Week17.32%
Market Cap758.59M Forward P/E- EPS next Y-1.48 Insider Trans-10.62% Shs Float53.69M Perf Month-26.74%
Income-80.90M PEG- EPS next Q-0.37 Inst Own89.00% Short Float3.97% Perf Quarter-6.66%
Sales6.40M P/S118.53 EPS this Y-33.20% Inst Trans4.62% Short Ratio4.38 Perf Half Y-15.94%
Book/sh2.93 P/B4.07 EPS next Y-3.70% ROA-31.40% Target Price34.80 Perf Year-48.11%
Cash/sh2.82 P/C4.22 EPS next 5Y- ROE-39.10% 52W Range9.26 - 24.00 Perf YTD-18.02%
Dividend- P/FCF- EPS past 5Y6.50% ROI-45.50% 52W High-50.33% Beta0.76
Dividend %- Quick Ratio11.40 Sales past 5Y- Gross Margin27.50% 52W Low28.73% ATR0.95
Employees75 Current Ratio11.40 Sales Q/Q-16.70% Oper. Margin- RSI (14)42.37 Volatility8.50% 7.38%
OptionableYes Debt/Eq0.00 EPS Q/Q46.50% Profit Margin- Rel Volume0.80 Prev Close12.32
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume487.17K Price11.92
Recom1.50 SMA20-5.94% SMA50-20.29% SMA200-18.91% Volume391,321 Change-3.25%
Jul-23-21Resumed Jefferies Buy $27 → $32
Jun-15-21Initiated Piper Sandler Overweight $30
Apr-21-21Initiated H.C. Wainwright Buy $40
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
May-17-22 11:53AM  
May-16-22 07:00AM  
May-10-22 08:15AM  
May-04-22 07:35PM  
May-03-22 07:00AM  
May-02-22 06:10AM  
Apr-13-22 12:17AM  
Feb-24-22 08:55AM  
Feb-21-22 04:34AM  
Feb-17-22 03:03PM  
Feb-06-22 04:33PM  
Feb-02-22 07:00AM  
Feb-01-22 04:01PM  
Jan-11-22 04:01PM  
Dec-27-21 07:00AM  
Dec-20-21 05:21PM  
Dec-08-21 11:59AM  
Dec-03-21 07:00AM  
Nov-23-21 04:13AM  
Nov-18-21 04:01PM  
Nov-03-21 07:00AM  
Nov-02-21 08:25AM  
Oct-27-21 03:03PM  
Oct-12-21 07:16PM  
Sep-29-21 08:47AM  
Sep-20-21 08:00AM  
Aug-26-21 04:01PM  
Aug-25-21 06:16AM  
Aug-05-21 10:58AM  
Jul-30-21 03:00PM  
Jul-08-21 07:00AM  
Jul-06-21 11:49AM  
Jun-09-21 07:55PM  
Jun-08-21 04:15PM  
May-18-21 01:25AM  
May-17-21 07:00AM  
May-07-21 08:35AM  
Apr-29-21 05:02PM  
Apr-26-21 01:39AM  
Mar-15-21 07:00AM  
Feb-25-21 07:00AM  
Feb-22-21 07:00AM  
Feb-10-21 07:00AM  
Jan-25-21 02:40PM  
Jan-20-21 01:25PM  
Jan-19-21 04:34PM  
Dec-28-20 11:17PM  
Dec-23-20 09:11AM  
Dec-15-20 11:26PM  
Nov-16-20 04:01PM  
Nov-14-20 07:08AM  
Nov-06-20 12:00PM  
Nov-04-20 08:25AM  
Oct-29-20 12:35PM  
Oct-21-20 10:46AM  
Oct-20-20 07:00AM  
Oct-14-20 10:36PM  
Oct-01-20 12:00PM  
Sep-30-20 06:40AM  
Sep-01-20 04:01PM  
Aug-13-20 12:00PM  
Aug-07-20 08:45AM  
Aug-06-20 12:30PM  
Jul-08-20 08:43AM  
Jul-07-20 04:01PM  
Jun-26-20 02:30PM  
Jun-18-20 10:12AM  
Jun-17-20 10:37AM  
Jun-03-20 07:00AM  
May-26-20 04:01PM  
May-12-20 10:47AM  
May-08-20 12:00PM  
May-07-20 04:01PM  
May-06-20 12:30PM  
Apr-09-20 06:13AM  
Apr-06-20 12:00PM  
Apr-01-20 11:07AM  
Mar-31-20 04:01PM  
Mar-17-20 02:46AM  
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker NealPresident and CEOApr 25Sale15.1820,000303,6561,245,763Apr 25 05:13 PM
Walker NealPresident and CEOApr 22Sale15.0425,000376,0981,265,763Apr 25 05:13 PM
Walker NealPresident and CEOApr 21Sale15.2425,000380,9481,290,763Apr 25 05:13 PM
Monahan JosephChief Scientific OfficerApr 18Sale16.2830,000488,298106,386Apr 20 05:06 PM
Walker NealPresident and CEOMar 11Sale15.9156,303896,0451,315,763Mar 14 04:58 PM
Ruffo FrankChief Financial OfficerMar 10Sale15.5512,823199,335201,883Mar 14 04:56 PM
Monahan JosephChief Scientific OfficerMar 10Sale15.7127,165426,803136,386Mar 14 04:53 PM
Monahan JosephChief Scientific OfficerFeb 09Sale12.683834,85787,301Feb 11 04:22 PM
Gordon David N.Chief Medical OfficerJul 13Sale16.982,63144,675147,447Jul 14 05:32 PM
Ali-Jackson KamilChief Legal OfficerJun 03Sale21.969,492208,421122,196Jun 04 07:52 PM
Monahan JosephChief Scientific OfficerJun 02Sale21.6421,790471,43785,342Jun 02 09:45 PM
Walker NealPresident and CEOJun 02Sale21.6433,260719,7351,232,182Jun 02 09:41 PM
Ali-Jackson KamilChief Legal OfficerJun 02Sale21.6430,119651,664131,688Jun 02 09:47 PM
Gordon David N.Chief Medical OfficerJun 02Sale21.6337,914820,209144,078Jun 02 09:49 PM
Gordon David N.Chief Medical OfficerJun 01Sale23.0114,000322,165181,992Jun 02 09:49 PM
Ali-Jackson KamilChief Legal OfficerJun 01Sale23.0215,000345,299161,807Jun 02 09:47 PM